At a glance
ClinicalIndex Comparison RecordN/ACompleted· 679 enrolled
Drug / intervention
denosumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Confirmatory Study of AMG 162 (Denosumab) in Patients With Rheumatoid Arthritis on DMARDs Treatment (Phase III)
In Brief
A clinical study evaluating denosumab and placebo for Rheumatoid Arthritis. Completed, enrolled 679 participants across 1 site.
Detailed Summary
To evaluate the inhibitory effect of progression, compared with placebo, in joint destruction by AMG 162 administered subcutaneously to rheumatoid arthritis participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesJapan
Collaborators--
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartOct 2013
First PostedOct 2013
Primary CompletionDec 2015
Study CompletionSep 2017
TodayJul 2026
First PostedOct 31, 2013
Enrollment StartOct 1, 2013
Primary CompletionDec 1, 2015
Study CompletionSep 19, 2017
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 12.7 years ago
Interventions
denosumabdrug
denosumab administered subcutaneously
placebodrug
placebo administered subcutaneously to match denosumab